Sierra Oncology, Inc.
Sierra Oncology, Inc. SRRA Peers
See (SRRA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRRA | $54.99 | N/A | 0 | -8.34 | -$6.59 | N/A |
| VRTX | $445.10 | -0.20% | 114.3B | -115.91 | -$3.84 | N/A |
| REGN | $591.43 | -1.96% | 62.8B | 15.04 | $39.33 | +0.30% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $285.56 | -1.56% | 37.2B | -136.63 | -$2.09 | N/A |
| ARGX | $576.24 | -0.61% | 35.2B | 35.16 | $16.39 | N/A |
| BNTX | $97.53 | -1.03% | 23.4B | -26.87 | -$3.63 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.04 | +1.56% | 19.2B | -76.59 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
SRRA vs VRTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, VRTX has a market cap of 114.3B. Regarding current trading prices, SRRA is priced at $54.99, while VRTX trades at $445.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas VRTX's P/E ratio is -115.91. In terms of profitability, SRRA's ROE is -0.98%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, SRRA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs REGN Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, REGN has a market cap of 62.8B. Regarding current trading prices, SRRA is priced at $54.99, while REGN trades at $591.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas REGN's P/E ratio is 15.04. In terms of profitability, SRRA's ROE is -0.98%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SRRA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs SGEN Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SRRA is priced at $54.99, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SRRA's ROE is -0.98%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, SRRA is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ALNY Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, SRRA is priced at $54.99, while ALNY trades at $285.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ALNY's P/E ratio is -136.63. In terms of profitability, SRRA's ROE is -0.98%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, SRRA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ARGX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ARGX has a market cap of 35.2B. Regarding current trading prices, SRRA is priced at $54.99, while ARGX trades at $576.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ARGX's P/E ratio is 35.16. In terms of profitability, SRRA's ROE is -0.98%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, SRRA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BNTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BNTX has a market cap of 23.4B. Regarding current trading prices, SRRA is priced at $54.99, while BNTX trades at $97.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BNTX's P/E ratio is -26.87. In terms of profitability, SRRA's ROE is -0.98%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SRRA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BGNE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SRRA is priced at $54.99, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SRRA's ROE is -0.98%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SRRA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs SMMT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, SMMT has a market cap of 19.2B. Regarding current trading prices, SRRA is priced at $54.99, while SMMT trades at $26.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas SMMT's P/E ratio is -76.59. In terms of profitability, SRRA's ROE is -0.98%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, SRRA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs DNA-WT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SRRA is priced at $54.99, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SRRA's ROE is -0.98%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, SRRA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RPRX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RPRX has a market cap of 18.3B. Regarding current trading prices, SRRA is priced at $54.99, while RPRX trades at $32.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RPRX's P/E ratio is 13.32. In terms of profitability, SRRA's ROE is -0.98%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, SRRA is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs UTHR Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, UTHR has a market cap of 14.2B. Regarding current trading prices, SRRA is priced at $54.99, while UTHR trades at $315.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas UTHR's P/E ratio is 12.58. In terms of profitability, SRRA's ROE is -0.98%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SRRA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs GMAB Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, GMAB has a market cap of 13.1B. Regarding current trading prices, SRRA is priced at $54.99, while GMAB trades at $21.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas GMAB's P/E ratio is 12.46. In terms of profitability, SRRA's ROE is -0.98%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SRRA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs KRTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SRRA is priced at $54.99, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SRRA's ROE is -0.98%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, SRRA is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs INCY Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, INCY has a market cap of 12.6B. Regarding current trading prices, SRRA is priced at $54.99, while INCY trades at $64.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas INCY's P/E ratio is 324.65. In terms of profitability, SRRA's ROE is -0.98%, compared to INCY's ROE of +0.01%. Regarding short-term risk, SRRA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs EXEL Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, EXEL has a market cap of 11.6B. Regarding current trading prices, SRRA is priced at $54.99, while EXEL trades at $42.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas EXEL's P/E ratio is 19.02. In terms of profitability, SRRA's ROE is -0.98%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, SRRA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BMRN Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, SRRA is priced at $54.99, while BMRN trades at $58.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BMRN's P/E ratio is 21.51. In terms of profitability, SRRA's ROE is -0.98%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SRRA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MRNA Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MRNA has a market cap of 10.1B. Regarding current trading prices, SRRA is priced at $54.99, while MRNA trades at $26.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MRNA's P/E ratio is -2.98. In terms of profitability, SRRA's ROE is -0.98%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SRRA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ASND Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ASND has a market cap of 9.6B. Regarding current trading prices, SRRA is priced at $54.99, while ASND trades at $159.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ASND's P/E ratio is -24.09. In terms of profitability, SRRA's ROE is -0.98%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SRRA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RXDX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SRRA is priced at $54.99, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SRRA's ROE is -0.98%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SRRA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRRA.
SRRA vs IMGN Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SRRA is priced at $54.99, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SRRA's ROE is -0.98%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, SRRA is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CORT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CORT has a market cap of 8.2B. Regarding current trading prices, SRRA is priced at $54.99, while CORT trades at $77.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CORT's P/E ratio is 67.52. In terms of profitability, SRRA's ROE is -0.98%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SRRA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CERE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SRRA is priced at $54.99, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CERE's P/E ratio is -16.47. In terms of profitability, SRRA's ROE is -0.98%, compared to CERE's ROE of -0.99%. Regarding short-term risk, SRRA is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ROIVW Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, SRRA is priced at $54.99, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SRRA's ROE is -0.98%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, SRRA is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ROIV Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ROIV has a market cap of 7.6B. Regarding current trading prices, SRRA is priced at $54.99, while ROIV trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ROIV's P/E ratio is -10.62. In terms of profitability, SRRA's ROE is -0.98%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, SRRA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs TECH Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, TECH has a market cap of 7.5B. Regarding current trading prices, SRRA is priced at $54.99, while TECH trades at $47.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas TECH's P/E ratio is 57.75. In terms of profitability, SRRA's ROE is -0.98%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SRRA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RVMD Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RVMD has a market cap of 7B. Regarding current trading prices, SRRA is priced at $54.99, while RVMD trades at $37.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RVMD's P/E ratio is -9.41. In terms of profitability, SRRA's ROE is -0.98%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, SRRA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs HALO Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, HALO has a market cap of 6.7B. Regarding current trading prices, SRRA is priced at $54.99, while HALO trades at $54.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas HALO's P/E ratio is 14.48. In terms of profitability, SRRA's ROE is -0.98%, compared to HALO's ROE of +1.22%. Regarding short-term risk, SRRA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs JAZZ Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, JAZZ has a market cap of 6.6B. Regarding current trading prices, SRRA is priced at $54.99, while JAZZ trades at $107.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas JAZZ's P/E ratio is 14.54. In terms of profitability, SRRA's ROE is -0.98%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, SRRA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RETA Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SRRA is priced at $54.99, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RETA's P/E ratio is -66.29. In terms of profitability, SRRA's ROE is -0.98%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SRRA is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs VRNA Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, VRNA has a market cap of 6.3B. Regarding current trading prices, SRRA is priced at $54.99, while VRNA trades at $73.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas VRNA's P/E ratio is -36.97. In terms of profitability, SRRA's ROE is -0.98%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SRRA is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BPMC Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BPMC has a market cap of 6.2B. Regarding current trading prices, SRRA is priced at $54.99, while BPMC trades at $95.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BPMC's P/E ratio is -37.97. In terms of profitability, SRRA's ROE is -0.98%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SRRA is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BBIO Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BBIO has a market cap of 6.1B. Regarding current trading prices, SRRA is priced at $54.99, while BBIO trades at $32.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BBIO's P/E ratio is -9.11. In terms of profitability, SRRA's ROE is -0.98%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, SRRA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MDGL Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MDGL has a market cap of 6B. Regarding current trading prices, SRRA is priced at $54.99, while MDGL trades at $270.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MDGL's P/E ratio is -15.18. In terms of profitability, SRRA's ROE is -0.98%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, SRRA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs TLX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, TLX has a market cap of 5.7B. Regarding current trading prices, SRRA is priced at $54.99, while TLX trades at $16.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas TLX's P/E ratio is 187.22. In terms of profitability, SRRA's ROE is -0.98%, compared to TLX's ROE of +0.14%. Regarding short-term risk, SRRA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs TGTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, SRRA is priced at $54.99, while TGTX trades at $35.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas TGTX's P/E ratio is 140.56. In terms of profitability, SRRA's ROE is -0.98%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, SRRA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ABCM Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SRRA is priced at $54.99, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SRRA's ROE is -0.98%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SRRA is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ISEE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SRRA is priced at $54.99, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SRRA's ROE is -0.98%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SRRA is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs IONS Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, IONS has a market cap of 5.2B. Regarding current trading prices, SRRA is priced at $54.99, while IONS trades at $32.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas IONS's P/E ratio is -10.84. In terms of profitability, SRRA's ROE is -0.98%, compared to IONS's ROE of -0.00%. Regarding short-term risk, SRRA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs NUVL Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, NUVL has a market cap of 5.1B. Regarding current trading prices, SRRA is priced at $54.99, while NUVL trades at $71.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas NUVL's P/E ratio is -16.16. In terms of profitability, SRRA's ROE is -0.98%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, SRRA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs AXSM Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, SRRA is priced at $54.99, while AXSM trades at $102.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas AXSM's P/E ratio is -17.85. In terms of profitability, SRRA's ROE is -0.98%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, SRRA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ALKS Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, SRRA is priced at $54.99, while ALKS trades at $29.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ALKS's P/E ratio is 14.24. In terms of profitability, SRRA's ROE is -0.98%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, SRRA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ADMA Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ADMA has a market cap of 4.7B. Regarding current trading prices, SRRA is priced at $54.99, while ADMA trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ADMA's P/E ratio is 23.23. In terms of profitability, SRRA's ROE is -0.98%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, SRRA is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ALPN Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SRRA is priced at $54.99, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SRRA's ROE is -0.98%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, SRRA and ALPN have similar daily volatility (0.05).
SRRA vs OPT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SRRA is priced at $54.99, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas OPT's P/E ratio is -1.52. In terms of profitability, SRRA's ROE is -0.98%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SRRA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRRA.
SRRA vs MRTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SRRA is priced at $54.99, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SRRA's ROE is -0.98%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, SRRA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs PCVX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, PCVX has a market cap of 4B. Regarding current trading prices, SRRA is priced at $54.99, while PCVX trades at $31.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas PCVX's P/E ratio is -7.86. In terms of profitability, SRRA's ROE is -0.98%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SRRA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs SLNO Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, SLNO has a market cap of 3.8B. Regarding current trading prices, SRRA is priced at $54.99, while SLNO trades at $75.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas SLNO's P/E ratio is -15.99. In terms of profitability, SRRA's ROE is -0.98%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, SRRA is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RYTM Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RYTM has a market cap of 3.8B. Regarding current trading prices, SRRA is priced at $54.99, while RYTM trades at $59.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RYTM's P/E ratio is -21.28. In terms of profitability, SRRA's ROE is -0.98%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, SRRA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RYZB Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SRRA is priced at $54.99, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SRRA's ROE is -0.98%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SRRA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SRRA.
SRRA vs PTCT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, PTCT has a market cap of 3.7B. Regarding current trading prices, SRRA is priced at $54.99, while PTCT trades at $47.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas PTCT's P/E ratio is 7.26. In terms of profitability, SRRA's ROE is -0.98%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, SRRA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CBAY Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SRRA is priced at $54.99, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SRRA's ROE is -0.98%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, SRRA is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RNA Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RNA has a market cap of 3.7B. Regarding current trading prices, SRRA is priced at $54.99, while RNA trades at $30.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RNA's P/E ratio is -10.30. In terms of profitability, SRRA's ROE is -0.98%, compared to RNA's ROE of -0.27%. Regarding short-term risk, SRRA is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ACAD Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, SRRA is priced at $54.99, while ACAD trades at $22.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ACAD's P/E ratio is 16.07. In terms of profitability, SRRA's ROE is -0.98%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, SRRA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs SRPT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, SRPT has a market cap of 3.7B. Regarding current trading prices, SRRA is priced at $54.99, while SRPT trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas SRPT's P/E ratio is -14.09. In terms of profitability, SRRA's ROE is -0.98%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, SRRA is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CYTK Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CYTK has a market cap of 3.6B. Regarding current trading prices, SRRA is priced at $54.99, while CYTK trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CYTK's P/E ratio is -5.72. In terms of profitability, SRRA's ROE is -0.98%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, SRRA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs AKRO Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, AKRO has a market cap of 3.6B. Regarding current trading prices, SRRA is priced at $54.99, while AKRO trades at $45.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas AKRO's P/E ratio is -12.18. In terms of profitability, SRRA's ROE is -0.98%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SRRA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs KRYS Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, KRYS has a market cap of 3.6B. Regarding current trading prices, SRRA is priced at $54.99, while KRYS trades at $123.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas KRYS's P/E ratio is 29.58. In terms of profitability, SRRA's ROE is -0.98%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, SRRA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs SWTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SRRA is priced at $54.99, while SWTX trades at $46.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas SWTX's P/E ratio is -13.69. In terms of profitability, SRRA's ROE is -0.98%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SRRA is less volatile compared to SWTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MRUS Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MRUS has a market cap of 3.5B. Regarding current trading prices, SRRA is priced at $54.99, while MRUS trades at $50.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MRUS's P/E ratio is -12.02. In terms of profitability, SRRA's ROE is -0.98%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, SRRA is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ACLX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ACLX has a market cap of 3.4B. Regarding current trading prices, SRRA is priced at $54.99, while ACLX trades at $61.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ACLX's P/E ratio is -20.45. In terms of profitability, SRRA's ROE is -0.98%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, SRRA is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs RARE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, RARE has a market cap of 3.2B. Regarding current trading prices, SRRA is priced at $54.99, while RARE trades at $34.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas RARE's P/E ratio is -5.89. In terms of profitability, SRRA's ROE is -0.98%, compared to RARE's ROE of -1.86%. Regarding short-term risk, SRRA is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CRSP Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CRSP has a market cap of 3.2B. Regarding current trading prices, SRRA is priced at $54.99, while CRSP trades at $37.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CRSP's P/E ratio is -8.29. In terms of profitability, SRRA's ROE is -0.98%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, SRRA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs VKTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, SRRA is priced at $54.99, while VKTX trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas VKTX's P/E ratio is -23.19. In terms of profitability, SRRA's ROE is -0.98%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, SRRA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CPRX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, SRRA is priced at $54.99, while CPRX trades at $24.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CPRX's P/E ratio is 15.63. In terms of profitability, SRRA's ROE is -0.98%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, SRRA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MTSR Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MTSR has a market cap of 2.9B. Regarding current trading prices, SRRA is priced at $54.99, while MTSR trades at $28.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MTSR's P/E ratio is -10.81. In terms of profitability, SRRA's ROE is -0.98%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, SRRA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MORF Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SRRA is priced at $54.99, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MORF's P/E ratio is -14.88. In terms of profitability, SRRA's ROE is -0.98%, compared to MORF's ROE of -0.27%. Regarding short-term risk, SRRA and MORF have similar daily volatility (0.05).
SRRA vs MOR Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SRRA is priced at $54.99, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MOR's P/E ratio is -12.64. In terms of profitability, SRRA's ROE is -0.98%, compared to MOR's ROE of +7.43%. Regarding short-term risk, SRRA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs PTGX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, PTGX has a market cap of 2.8B. Regarding current trading prices, SRRA is priced at $54.99, while PTGX trades at $45.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas PTGX's P/E ratio is 58.65. In terms of profitability, SRRA's ROE is -0.98%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, SRRA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CRNX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, SRRA is priced at $54.99, while CRNX trades at $29.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CRNX's P/E ratio is -7.87. In terms of profitability, SRRA's ROE is -0.98%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, SRRA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs SRRK Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, SRRK has a market cap of 2.7B. Regarding current trading prices, SRRA is priced at $54.99, while SRRK trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas SRRK's P/E ratio is -11.32. In terms of profitability, SRRA's ROE is -0.98%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, SRRA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs KDNY Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, SRRA is priced at $54.99, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SRRA's ROE is -0.98%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SRRA is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MYOV Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, SRRA is priced at $54.99, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SRRA's ROE is -0.98%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SRRA is less volatile compared to MYOV. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs LEGN Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, LEGN has a market cap of 2.6B. Regarding current trading prices, SRRA is priced at $54.99, while LEGN trades at $28.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas LEGN's P/E ratio is -23.97. In terms of profitability, SRRA's ROE is -0.98%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, SRRA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MLTX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MLTX has a market cap of 2.4B. Regarding current trading prices, SRRA is priced at $54.99, while MLTX trades at $38.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MLTX's P/E ratio is -16.60. In terms of profitability, SRRA's ROE is -0.98%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, SRRA is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs IMVT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, IMVT has a market cap of 2.4B. Regarding current trading prices, SRRA is priced at $54.99, while IMVT trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas IMVT's P/E ratio is -5.38. In terms of profitability, SRRA's ROE is -0.98%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, SRRA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs PRVB Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, SRRA is priced at $54.99, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SRRA's ROE is -0.98%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SRRA is less volatile compared to PRVB. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs LBPH Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, SRRA is priced at $54.99, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SRRA's ROE is -0.98%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, SRRA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for SRRA.
SRRA vs DICE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, SRRA is priced at $54.99, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas DICE's P/E ratio is -21.91. In terms of profitability, SRRA's ROE is -0.98%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SRRA is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BCRX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BCRX has a market cap of 2.2B. Regarding current trading prices, SRRA is priced at $54.99, while BCRX trades at $10.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BCRX's P/E ratio is -39.11. In terms of profitability, SRRA's ROE is -0.98%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, SRRA is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs XENE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, XENE has a market cap of 2.2B. Regarding current trading prices, SRRA is priced at $54.99, while XENE trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas XENE's P/E ratio is -8.85. In terms of profitability, SRRA's ROE is -0.98%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SRRA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs APGE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, SRRA is priced at $54.99, while APGE trades at $36.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas APGE's P/E ratio is -10.08. In terms of profitability, SRRA's ROE is -0.98%, compared to APGE's ROE of -0.19%. Regarding short-term risk, SRRA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs IBRX Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, SRRA is priced at $54.99, while IBRX trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas IBRX's P/E ratio is -4.31. In terms of profitability, SRRA's ROE is -0.98%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, SRRA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs MIRM Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, MIRM has a market cap of 2.2B. Regarding current trading prices, SRRA is priced at $54.99, while MIRM trades at $43.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas MIRM's P/E ratio is -27.16. In terms of profitability, SRRA's ROE is -0.98%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, SRRA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CALT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, SRRA is priced at $54.99, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CALT's P/E ratio is -22.73. In terms of profitability, SRRA's ROE is -0.98%, compared to CALT's ROE of -2.10%. Regarding short-term risk, SRRA is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs ARWR Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, SRRA is priced at $54.99, while ARWR trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas ARWR's P/E ratio is -12.34. In terms of profitability, SRRA's ROE is -0.98%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, SRRA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs VCEL Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, SRRA is priced at $54.99, while VCEL trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas VCEL's P/E ratio is 842.00. In terms of profitability, SRRA's ROE is -0.98%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, SRRA is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs AAPG Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, AAPG has a market cap of 2.1B. Regarding current trading prices, SRRA is priced at $54.99, while AAPG trades at $24.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas AAPG's P/E ratio is -33.01. In terms of profitability, SRRA's ROE is -0.98%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, SRRA is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs APLS Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, APLS has a market cap of 2.1B. Regarding current trading prices, SRRA is priced at $54.99, while APLS trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas APLS's P/E ratio is -9.33. In terms of profitability, SRRA's ROE is -0.98%, compared to APLS's ROE of -1.00%. Regarding short-term risk, SRRA is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs VCYT Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, SRRA is priced at $54.99, while VCYT trades at $26.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas VCYT's P/E ratio is 63.60. In terms of profitability, SRRA's ROE is -0.98%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SRRA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs BLTE Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, SRRA is priced at $54.99, while BLTE trades at $61.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas BLTE's P/E ratio is -45.30. In terms of profitability, SRRA's ROE is -0.98%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, SRRA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs KNSA Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, SRRA is priced at $54.99, while KNSA trades at $27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas KNSA's P/E ratio is -113.54. In terms of profitability, SRRA's ROE is -0.98%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, SRRA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs NAMS Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, NAMS has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while NAMS trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas NAMS's P/E ratio is -9.41. In terms of profitability, SRRA's ROE is -0.98%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, SRRA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs HRMY Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, HRMY has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while HRMY trades at $33.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas HRMY's P/E ratio is 12.87. In terms of profitability, SRRA's ROE is -0.98%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, SRRA is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs LGND Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, LGND has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while LGND trades at $100.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas LGND's P/E ratio is -13.74. In terms of profitability, SRRA's ROE is -0.98%, compared to LGND's ROE of -0.16%. Regarding short-term risk, SRRA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs CGON Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, CGON has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while CGON trades at $25.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas CGON's P/E ratio is -16.85. In terms of profitability, SRRA's ROE is -0.98%, compared to CGON's ROE of -0.17%. Regarding short-term risk, SRRA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs GLPG Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, GLPG has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while GLPG trades at $29.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas GLPG's P/E ratio is -9.43. In terms of profitability, SRRA's ROE is -0.98%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, SRRA is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs DNLI Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, DNLI has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while DNLI trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas DNLI's P/E ratio is -4.88. In terms of profitability, SRRA's ROE is -0.98%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, SRRA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs FOLD Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, FOLD has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while FOLD trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas FOLD's P/E ratio is -67.78. In terms of profitability, SRRA's ROE is -0.98%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, SRRA is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.
SRRA vs KYMR Comparison
SRRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRA stands at 0. In comparison, KYMR has a market cap of 1.9B. Regarding current trading prices, SRRA is priced at $54.99, while KYMR trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRA currently has a P/E ratio of -8.34, whereas KYMR's P/E ratio is -9.26. In terms of profitability, SRRA's ROE is -0.98%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, SRRA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for SRRA.